Fe3O4/Salicylic acid nanoparticles behavior on chick CAM vasculature
Source abstract
Abstract
A modified ferrite co-precipitation synthesis was used to obtain core–shell Fe3O4/salicylic acid magnetic nanoparticles (Sa-MNP) with well-dispersed aqueous solution properties. The newly developed iron oxide nanoparticles properties were investigated with X-ray diffraction, Fourier transform infrared spectrometry, transmission electron microscopy, and laser light scattering for their characteristic establishment. The resulting Sa-MNPs have spherical morphology, homogenous size distribution around 60 nm (35 nm FWHM), and a 67 mV Zeta potential value (15.5 mV STDV). In vivo biocompatibility and intravascular behavior of the 60 nm diameter size range synthesized nanoparticles were evaluated on chick chorioallantoic membrane model. The results show a reversible and good controlled intravascular accumulation under static magnetic field, a low risk of embolisation with nanoparticle aggregates detached from venous intravascular nanoblocked areas, a persistent blocking of the arterioles and dependent capillaries network, a good circulating life time and biocompatibility. The beneficial effects of salicylic acid (SA) and in vivo demonstrated capacity of Sa-MNPs to cutoff regional vascular supply under static magnetic field control suggest a possible biomedical application of these MNPs in targeted cancer therapy through magnetic controlled blood flow nanoblocking mechanism.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles · Barrier Structure and Function Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Baron JA (2009) Aspirin and NSAIDs for the prevention of colorectal cancer. Recent Results Cancer Res 181:223–22910.1007/978-3-540-69297-3_21 ↗
2. Berry CC, Curtis ASG (2003) Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D 36:R198–R20610.1088/0022-3727/36/13/203 ↗
3. Berry CC, Wells S, Charles S, Curtis AS (2003) Dextran and albumin derivatised iron oxide nanoparticles: influence on fibroblasts in vitro. Biomaterials 24:4551–455710.1016/S0142-9612(03)00237-0 ↗
4. Blacklock CJ, Lawrence JR, Wiles D, Malcolm EA, Gibson IH, Kelly CJ et al (2001) Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians, and patients taking low dose aspirin. J Clin Pathol 54:553–55510.1136/jcp.54.7.553 ↗
5. Cheng FY, Su CH, Yang YS, Yeh CS, Tsai CY, Wu CL et al (2005) Characterization of aqueous dispersions of Fe3O4 nanoparticles and their biomedical applications. Biomaterials 26:729–73810.1016/j.biomaterials.2004.03.016 ↗
6. Chomouckaa J, Drbohlavovaa J, Huskab D, Adamb V, Kizekb R, Hubaleka J (2010) Magnetic nanoparticles and targeted drug delivering. Pharmacol Res 62:144–14910.1016/j.phrs.2010.01.014 ↗
7. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ et al (2009) Aspirin for the chemoprevention of colorectal adenomas: metaanalysis of the randomized trials. J Natl Cancer I 101:256–26610.1093/jnci/djn485 ↗
8. Cole JA, Yang CV, David AE (2011) Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol 29:323–33210.1016/j.tibtech.2011.03.001 ↗
9. Faivre D, Schuler D (2008) Magnetic bacteria and magnetosomes. Chem Rev 108:4875–489810.1021/cr078258w ↗
10. Figuerola A, Di Corato R, Manna L, Pellegrino T (2010) From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res 62:126–14310.1016/j.phrs.2009.12.012 ↗
11. Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra A, Ghosh PK (2000) Biodistribution of fluoresceinated dextran using novel, nanoparticles evading reticuloendothelial system. Int J Pharm 202:1–1010.1016/S0378-5173(99)00447-0 ↗
12. Gruttner C, Teller J (1999) New types of silica-fortified magnetic nanoparticles as tools for molecular biology applications. J Magn Magn Mater 194:8–1510.1016/S0304-8853(98)00561-7 ↗
13. Gupta AK, Wells S (2004) Surface-modified superparamagnetic nanoparticles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE T Nanobiosci 3:66–7310.1109/TNB.2003.820277 ↗
14. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363–138010.1016/S0002-9440(10)65006-7 ↗
15. Huang HC, Barua S, Sharma G, Dey SK, Rege K (2011) Inorganic nanoparticles for cancer imaging and therapy. J Control Release 155:257–34410.1016/j.jconrel.2011.06.004 ↗
16. Ito A, Shinkai M, Honda H, Kobayashi T (2005) Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng 100:1–1110.1263/jbb.100.1 ↗
17. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V (2008) Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm 5:316–32710.1021/mp7001285 ↗
18. Kayal S, Ramanujan RV (2010) Anti-cancer drug loaded iron gold core–shell nanoparticles (Fe@Au) for magnetic drug targeting. J Nanosci Nanotechnol 10:1–1310.1166/jnn.2010.2461 ↗
19. Laurent S, Dutz S, Häfeli OU, Mahmoudi M (2011) Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. Adv Colloid Interface Sci 166:8–2310.1016/j.cis.2011.04.003 ↗
20. Lu AH, Salabas EL, Schuth F (2007) Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Edit 46:1222–124410.1002/anie.200602866 ↗
21. Luo T, Yan HM, He P, Luo Y, Yang YF, Zheng H (2012) Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Tr 131(2):581–58710.1007/s10549-011-1747-0 ↗
22. McCarthy JR, Weissleder R (2008) Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 60:1241–125110.1016/j.addr.2008.03.014 ↗
23. Medeiros SF, Santos AM, Fessi H, Elaissari A (2011) Stimuli-responsive magnetic particles for biomedical applications. Int J Pharm 403:139–16110.1016/j.ijpharm.2010.10.011 ↗
24. Neuberger T, Schopf B, Hofmann H, Hofmann M, Vonrechenberg B (2005) Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater 293:483–49610.1016/j.jmmm.2005.01.064 ↗
25. Paterson JR, Lawrence JR (2001) Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer. Q J Med 94:445–44810.1093/qjmed/94.8.445 ↗
26. Praetorius NP, Mandal TK (2007) Engineered nanoparticles in cancer therapy. Recent Pat Drug Deliv Formul 1:37–5110.2174/187221107779814104 ↗
27. Purushotham S, Ramanujan RV (2010) Thermoresponsive magnetic composite nanomaterials for multimodal cancer therapy. Acta Biomater 6:502–51010.1016/j.actbio.2009.07.004 ↗
28. Qianqian O, Lei Z, Shengguo Z, Huijuan G, Junjie H, Yinyin X et al (2012) Self-templated synthesis of bifunctional Fe3O4@MgSiO3 magnetic sub-microspheres for toxic metal ions removal. Chem Eng J 180:121–12710.1016/j.cej.2011.11.022 ↗
29. Reimer P, Balzer T (2003) Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–127610.1007/s00330-002-1721-7 ↗
30. Satchell SC, Braet F (2009) Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol 296:947–95610.1152/ajprenal.90601.2008 ↗
31. Schreinmachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138–14610.1097/00001648-199403000-00003 ↗
32. Singh N, Jenkins G, Asadi R, Doak SH (2010) Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. doi: 10.3402/nano.v1i0.5358
33. Sokolov ND (1984) On the mechanism of the broadening of the proton vibrational IR band in weak hydrogen bonds.Double adiabatic approximation. J Mol Liq 29:231–24210.1016/0167-7322(84)80052-5 ↗
34. Spitz GA, Furtado CM, Sola-Penna M, Zancan P (2009) Acetylsalicylic acid and salicylic acid decrease tumor cell viability and glucose metabolism modulating 6-phosphofructo-1-kinase structure and activity. Biochem Pharmacol 77:46–5310.1016/j.bcp.2008.09.020 ↗
35. Taupitz M, Schnorr J, Abramjuk C, Wagner S, Pilgrimm H, Hunigen H et al (2000) New generation of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: preclinical results in rats and rabbits. J Magn Reson Imaging 12:905–91110.1002/1522-2586(200012)12:6<905::AID-JMRI14>3.0.CO;2-5 ↗
36. Taupitz M, Schnorr J, Wagner S, Abramjuk C, Pilgrimm H, Kivelitz D et al (2002) Coronary MR angiography: experimental results with a mono-mer-stabilized blood pool contrast medium. Radiology 222:120–12610.1148/radiol.2221001452 ↗
37. Vainio H, Morgan G (1998) Cyclo-oxygenase 2 and breast cancer prevention. BMJ 317:828–83010.1136/bmj.317.7162.828 ↗
38. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP et al (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–3756